{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T00:28:51Z","timestamp":1794011331879,"version":"4.8.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T00:00:00Z","timestamp":1674950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T00:00:00Z","timestamp":1674950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Bipolar Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lithium is well recognized as the first-line maintenance treatment for bipolar disorder (BD). However, besides therapeutic benefits attributed to lithium therapy, the associated side effects including endocrinological and renal disorders constitute important parameters in prescribing patterns and patient adherence. The objectives of this study is to (i) determine whether long-term lithium therapy is associated with a decrease in renal function, hyperparathyroidism and hypercalcemia and (ii) identify risk factors for lithium-induced chronic kidney disease (CKD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a single-centered cohort study of adult patients (\u2265\u200918\u00a0years) treated with lithium, who were enrolled at Rennes University Hospital in France between January 1, 2018 and June 1, 2020. Required data were collected from the patient\u2019s medical records: demographics characteristics (age, sex, body mass index), biologic parameters (GFR, lithium blood level, PTH and calcium), medical comorbidities (hypertension and diabetes), lithium treatment duration and dosage, and length of hospitalization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 248 patients were included (mean age: 60.2\u2009\u00b1\u200916.5\u00a0years). Duration of lithium treatment correlated with (i) deterioration of renal function estimated at \u2212\u00a02.9\u00a0mL\/min\/year (p\u2009&lt;\u20090.0001) and (ii) the development of hyperparathyroidism (p\u2009&lt;\u20090.01) and hypercalcemia (p\u2009&lt;\u20090.01). We also noted that patients with lithium blood level\u2009&gt;\u20090.8\u00a0mEq\/mL had significantly lower GFR than patients with lithium blood level\u2009&lt;\u20090.8\u00a0mEq\/mL (61.8\u00a0mL\/min versus 77.6\u00a0mL\/min, respectively, p\u2009=\u20090.0134). Neither diabetes mellitus nor hypertension was associated with more rapid deterioration of renal function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study suggests that the duration of lithium treatment contribute to the deterioration of renal function, raising the question of reducing dosages in patients with a GFR\u2009&lt;\u200960\u00a0mL\/min. Overdoses has been identified as a risk factor for CKD, emphasizing the importance of regular re-evaluation of the lithium dose regimen. Also, long-term lithium therapy was associated with hyperparathyroidism and hypercalcemia. Particular vigilance is required on these points in order to limit the occurrence of endocrinological and renal lithium adverse effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40345-023-00286-8","type":"journal-article","created":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T11:03:37Z","timestamp":1674990217000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Long-term lithium therapy and risk of chronic kidney disease, hyperparathyroidism and hypercalcemia: a cohort study"],"prefix":"10.1186","volume":"11","author":[{"given":"Elise","family":"Boivin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Le Dar\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Bellay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Vigneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Mercerolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Bacle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,29]]},"reference":[{"issue":"1","key":"286_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40345-015-0028-y","volume":"3","author":"AN Azab","year":"2015","unstructured":"Azab AN, Shnaider A, Osher Y, Wang D, Bersudsky Y, Belmaker RH. Lithium nephrotoxicity. Int J Bipolar Disord. 2015;3(1):13.","journal-title":"Int J Bipolar Disord"},{"issue":"10","key":"286_CR2","doi-asserted-by":"publisher","first-page":"468","DOI":"10.4236\/ss.2011.210103","volume":"02","author":"UK Ballehaninna","year":"2011","unstructured":"Ballehaninna UK, Nguyen SM, Chamberlain RS. Lithium associated hyperparathyroidism: an evidence based surgical approach. SS. 2011;02(10):468\u201375.","journal-title":"SS"},{"issue":"7","key":"286_CR3","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJM198502143120705","volume":"312","author":"DC Batlle","year":"1985","unstructured":"Batlle DC, von Riotte AB, Gaviria M, Grupp M. Amelioration of polyuria by amiloride in patients receiving long-term lithium therapy. N Engl J Med. 1985;312(7):408\u201314.","journal-title":"N Engl J Med"},{"issue":"5","key":"286_CR4","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.2215\/CJN.01640408","volume":"3","author":"JJ Bedford","year":"2008","unstructured":"Bedford JJ, Weggery S, Ellis G, McDonald FJ, Joyce PR, Leader JP, et al. Lithium-induced nephrogenic diabetes insipidus: renal effects of amiloride. CJASN. 2008;3(5):1324\u201331.","journal-title":"CJASN"},{"issue":"10","key":"286_CR5","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nrneph.2015.89","volume":"11","author":"D Bockenhauer","year":"2015","unstructured":"Bockenhauer D, Bichet DG. Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus. Nat Rev Nephrol. 2015;11(10):576\u201388.","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"286_CR6","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S2215-0366(15)00316-8","volume":"2","author":"S Clos","year":"2015","unstructured":"Clos S, Rauchhaus P, Severn A, Cochrane L, Donnan PT. Long-term effect of lithium maintenance therapy on estimated glomerular filtration rate in patients with affective disorders: a population-based cohort study. Lancet Psychiatry. 2015;2(12):1075\u201383.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"286_CR7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1053\/j.ajkd.2016.11.005","volume":"69","author":"AB Fogo","year":"2017","unstructured":"Fogo AB, Lusco MA, Andeen NK, Najafian B, Alpers CE. AJKD atlas of renal pathology: lithium nephrotoxicity. Am J Kidney Dis. 2017;69(1):e1-2.","journal-title":"Am J Kidney Dis"},{"issue":"9878","key":"286_CR8","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S0140-6736(13)60857-0","volume":"381","author":"JR Geddes","year":"2013","unstructured":"Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013;381(9878):1672\u201382.","journal-title":"Lancet"},{"issue":"1","key":"286_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40345-016-0068-y","volume":"4","author":"M Gitlin","year":"2016","unstructured":"Gitlin M. Lithium side effects and toxicity: prevalence and management strategies. Int J Bipolar Disord. 2016;4(1):27.","journal-title":"Int J Bipolar Disord"},{"issue":"1","key":"286_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000445450","volume":"134","author":"RJ Glassock","year":"2016","unstructured":"Glassock RJ, Rule AD. Aging and the kidneys: anatomy, physiology and consequences for defining chronic kidney disease. Nephron. 2016;134(1):25\u20139.","journal-title":"Nephron"},{"issue":"6","key":"286_CR11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/0269881116636545","volume":"30","author":"G Goodwin","year":"2016","unstructured":"Goodwin G, Haddad P, Ferrier I, Aronson J, Barnes T, Cipriani A, et al. Evidence based guidelines for treating bipolar disorder: revised third edition recommendations from the British association for psychopharmacology. J Psychopharmacol. 2016;30(6):495\u2013553.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"286_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1192\/pb.bp.116.054031","volume":"41","author":"S Gupta","year":"2017","unstructured":"Gupta S, Khastgir U. Drug information update. lithium and chronic kidney disease: debates and dilemmas. BJPsych Bull. 2017;41(4):216\u201320.","journal-title":"BJPsych Bull"},{"issue":"5","key":"286_CR13","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/j.1600-0447.1986.tb02727.x","volume":"73","author":"O Hetmar","year":"1986","unstructured":"Hetmar O, Bolwig TG, Brun C, Ladefoged J, Larsen S, Rafaelsen OJ. Lithium: long-term effects on the kidney I. renal function in retrospect. Acta Psychiatr Scand. 1986;73(5):574\u201381.","journal-title":"Acta Psychiatr Scand"},{"issue":"7","key":"286_CR14","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/ncpneph0525","volume":"3","author":"W Khairallah","year":"2007","unstructured":"Khairallah W, Fawaz A, Brown EM, El-Hajj FG. Hypercalcemia and diabetes insipidus in a patient previously treated with lithium. Nat Rev Nephrol. 2007;3(7):397\u2013404.","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"286_CR15","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.bbagen.2013.12.002","volume":"1840","author":"MLA Kortenoeven","year":"2014","unstructured":"Kortenoeven MLA, Fenton RA. Renal aquaporins and water balance disorders. Biochim Biophys Acta. 2014;1840(5):1533\u201349.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"286_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/ki.2009.91","volume":"76","author":"MLA Kortenoeven","year":"2009","unstructured":"Kortenoeven MLA, Li Y, Shaw S, Gaeggeler H-P, Rossier BC, Wetzels JFM, et al. Amiloride blocks lithium entry through the sodium channel thereby attenuating the resultant nephrogenic diabetes insipidus. Kidney Int. 2009;76(1):44\u201353.","journal-title":"Kidney Int"},{"issue":"jul03 1","key":"286_CR17","doi-asserted-by":"publisher","first-page":"b2452","DOI":"10.1136\/bmj.b2452","volume":"339","author":"M Kripalani","year":"2009","unstructured":"Kripalani M, Shawcross J, Reilly J, Main J. Lithium and chronic kidney disease. BMJ. 2009;339(jul03 1):b2452\u2013b2452.","journal-title":"BMJ"},{"issue":"11","key":"286_CR18","doi-asserted-by":"publisher","first-page":"6109","DOI":"10.3390\/ijms22116109","volume":"22","author":"E Kwiatkowska","year":"2021","unstructured":"Kwiatkowska E, Doma\u0144ski L, Dziedziejko V, Kajdy A, Stefa\u0144ska K, Kwiatkowski S. The mechanism of drug nephrotoxicity and the methods for preventing kidney damage. IJMS. 2021;22(11):6109.","journal-title":"IJMS"},{"issue":"2","key":"286_CR19","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jad.2012.08.028","volume":"146","author":"SW Lehmann","year":"2013","unstructured":"Lehmann SW, Lee J. Lithium-associated hypercalcemia and hyperparathyroidism in the elderly: what do we know? J Affect Disord. 2013;146(2):151\u20137.","journal-title":"J Affect Disord"},{"key":"286_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/14651858.CD003834.pub3","volume":"2015","author":"S Leucht","year":"2015","unstructured":"Leucht S, Helfer B, Dold M, Kissling W, McGrath JJ. Lithium for schizophrenia. cochrane schizophrenia group, editor. Cochrane Database Syst Rev. 2015;2015:10. https:\/\/doi.org\/10.1002\/14651858.CD003834.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"286_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4158\/EP.2.2.103","volume":"2","author":"CR McHenry","year":"1996","unstructured":"McHenry CR, Lee K. Lithium therapy and disorders of the parathyroid glands. Endocr Pract. 1996;2(2):103\u20139.","journal-title":"Endocr Pract"},{"issue":"11","key":"286_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2020.0457","volume":"81","author":"S Mifsud","year":"2020","unstructured":"Mifsud S, Cilia K, Mifsud EL, Gruppetta M. Lithium-associated hyperparathyroidism. Br J Hosp Med. 2020;81(11):1\u20139.","journal-title":"Br J Hosp Med"},{"issue":"8","key":"286_CR23","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/cpdd.879","volume":"9","author":"H Mody","year":"2020","unstructured":"Mody H, Ramakrishnan V, Chaar M, Lezeau J, Rump A, Taha K, et al. A review on drug-induced nephrotoxicity: pathophysiological mechanisms, drug classes, clinical management, and recent advances in mathematical modeling and simulation approaches. Clin Pharmacol Drug Dev. 2020;9(8):896\u2013909.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"286_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1192\/bjp.bp.108.051268","volume":"193","author":"R Morriss","year":"2008","unstructured":"Morriss R, Benjamin B. Lithium and eGFR: a new routinely available tool for the prevention of chronic kidney disease. Br J Psychiatry. 2008;193(2):93\u20135.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"286_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.18773\/austprescr.2001.009","volume":"24","author":"BJ Nankivell","year":"2001","unstructured":"Nankivell BJ. Abnormal laboratory results: creatinine clearance and the assessment of renal function. Aust Prescr. 2001;24(1):15\u20137.","journal-title":"Aust Prescr"},{"issue":"6","key":"286_CR26","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/j.1399-5618.2009.00737.x","volume":"11","author":"F Ng","year":"2009","unstructured":"Ng F, Mammen OK, Wilting I, Sachs GS, Ferrier IN, Cassidy F, et al. the international society for bipolar disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord. 2009;11(6):559\u201395.","journal-title":"Bipolar Disord"},{"issue":"4","key":"286_CR27","first-page":"207","volume":"158","author":"J Nordenstr\u00f6m","year":"1992","unstructured":"Nordenstr\u00f6m J, Strig\u00e5rd K, Perbeck L, Willems J, B\u00e5gedahl-Strindlund M, Linder J. Hyperparathyroidism associated with treatment of manic-depressive disorders by lithium. Eur J Surg. 1992;158(4):207\u201311.","journal-title":"Eur J Surg"},{"issue":"7","key":"286_CR28","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/bdi.13052","volume":"23","author":"M Pahwa","year":"2021","unstructured":"Pahwa M, Joseph B, Nunez NA, Jenkins GD, Colby CL, Kashani KB, et al. Long-term lithium therapy and risk of chronic kidney disease in bipolar disorder: a historical cohort study. Bipolar Disord. 2021;23(7):715\u201323.","journal-title":"Bipolar Disord"},{"issue":"12","key":"286_CR29","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.2215\/CJN.00150118","volume":"13","author":"MA Perazella","year":"2018","unstructured":"Perazella MA. Pharmacology behind common drug nephrotoxicities. CJASN. 2018;13(12):1897\u2013908.","journal-title":"CJASN"},{"key":"286_CR30","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11290821","author":"MA Perazella","year":"2022","unstructured":"Perazella MA, Rosner MH. Drug-induced acute kidney. Injury. 2022. https:\/\/doi.org\/10.2215\/CJN.11290821.","journal-title":"Injury"},{"issue":"2","key":"286_CR31","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1046\/j.1523-1755.2003.00096.x","volume":"64","author":"C Presne","year":"2003","unstructured":"Presne C, Fakhouri F, No\u00ebl L-H, Stengel B, Even C, Kreis H, et al. Lithium-induced nephropathy: rate of progression and prognostic factors. Kidney Int. 2003;64(2):585\u201392.","journal-title":"Kidney Int"},{"issue":"1","key":"286_CR32","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/0891988712436690","volume":"25","author":"S Rej","year":"2012","unstructured":"Rej S, Herrmann N, Shulman K. The effects of lithium on renal function in older adults\u2014a systematic review. J Geriatr Psychiatry Neurol. 2012;25(1):51\u201361.","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"3","key":"286_CR33","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.kint.2017.02.036","volume":"92","author":"R Schmitt","year":"2017","unstructured":"Schmitt R, Melk A. Molecular mechanisms of renal aging. Kidney Int. 2017;92(3):569\u201379.","journal-title":"Kidney Int"},{"issue":"9992","key":"286_CR34","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(14)61842-0","volume":"386","author":"B Shine","year":"2015","unstructured":"Shine B, McKnight RF, Leaver L, Geddes JR. Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet. 2015;386(9992):461\u20138.","journal-title":"Lancet"},{"issue":"2","key":"286_CR35","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1530\/EJE-08-0620","volume":"160","author":"A Szalat","year":"2009","unstructured":"Szalat A, Mazeh H, Freund HR. Lithium-associated hyperparathyroidism: report of four cases and review of the literature. Eur J Endocrinol. 2009;160(2):317\u201323.","journal-title":"Eur J Endocrinol"},{"key":"286_CR36","unstructured":"Tees Esk and Wear Valley NHS Foundation Trust. Guidelines on safe lithium prescribing and shared care. 2021. https:\/\/www.tewv.nhs.uk\/content\/uploads\/2022\/01\/Lithium-Shared-Care-Guidelines.pdf?UNLID=98991256620224215212"},{"issue":"3","key":"286_CR37","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1681\/ASN.V103666","volume":"10","author":"RT Timmer","year":"1999","unstructured":"Timmer RT, Sands JM. Lithium intoxication. JASN. 1999;10(3):666\u201374.","journal-title":"JASN"},{"issue":"8","key":"286_CR38","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1177\/02698811211013579","volume":"35","author":"GH V\u00e1zquez","year":"2021","unstructured":"V\u00e1zquez GH, Bahji A, Undurraga J, Tondo L, Baldessarini RJ. Efficacy and tolerability of combination treatments for major depression: antidepressants plus second-generation antipsychotics vs esketamine vs lithium. J Psychopharmacol. 2021;35(8):890\u2013900.","journal-title":"J Psychopharmacol"},{"issue":"2","key":"286_CR39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","volume":"20","author":"LN Yatham","year":"2018","unstructured":"Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97\u2013170.","journal-title":"Bipolar Disord"}],"container-title":["International Journal of Bipolar Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40345-023-00286-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40345-023-00286-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40345-023-00286-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T11:10:50Z","timestamp":1674990650000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalbipolardisorders.springeropen.com\/articles\/10.1186\/s40345-023-00286-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,29]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["286"],"URL":"https:\/\/doi.org\/10.1186\/s40345-023-00286-8","relation":{},"ISSN":["2194-7511"],"issn-type":[{"value":"2194-7511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,29]]},"assertion":[{"value":"9 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was waived in view of the retrospective nature of the study and all the procedures being performed were part of the routine care.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We have a waiver of patient consents to participate and for publication due to the retrospective nature of the data, the anonymization of the data and the fact that all procedures presented in this article were performed as part of routine care.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent of publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}